Why Is It Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on Biologics Advancements in the Ophthalmic Disease Treatment Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Scope of Analysis

Segmentation

Growth Drivers

Growth Driver Analysis

Growth Driver Analysis (continued)

Growth Restraints

Growth Restraint Analysis

Growth Restraint Analysis (continued)

The Prevalence of and Rise in Unmet Needs in Ophthalmic Diseases

The Prevalence of and Rise in Unmet Needs in Ophthalmic Diseases (continued)

The Growing Importance of Biologics for Ocular Diseases

Focus Areas of Ophthalmic Disease Management

The Current Treatment Landscape of Ophthalmic Diseases

Gene-based/Mutation-specific Approaches: DNA Therapy

Gene-based/Mutation-specific Approaches: RNA Therapy

Challenges in Gene-based Approaches

Challenges in Gene-based Approaches (continued)

R&D Focus Areas in Gene-based Approaches

Notable Companies Developing Gene Therapy

Notable Companies Developing Gene Therapy: Clinical Pipelines

Disease Landscape, Clinical Phase, and Delivery Analysis

Key Innovators: DNA-based Therapy

Key Innovators: RNA-based Therapy

Treatment of Late-stage Retinal Degeneration by Optogenetics

Treatment of Late-stage Retinal Degeneration by Optogenetics (continued)

Clinical Pipeline of Key Players Working on Optogenetics

Key Innovators: Optogenetics

Non-genetic Approaches

Multi-inhibition to Efficiently Block Angiogenesis

Key Innovators: Protein-based

Non-genetic Approaches

Non-genetic Approaches

Non-genetic Approaches (continued)

Key Innovators: Stem Cell Therapy

Retinitis Pigmentosa

Age-related Macular Degeneration

Approaches for Treating Most Researched Ophthalmic Diseases

Clinical Trial Assessment of Ophthalmologic Diseases

Delivery Innovations for Ophthalmic Diseases

Innovations to Efficiently Deliver Ophthalmic Drugs

Emerging Delivery Systems for Ophthalmic Drug Delivery

Emerging Delivery Systems for Ophthalmic Drug Delivery (continued)

Emerging Delivery Systems for Ophthalmic Drug Delivery (continued)

Emerging Delivery Systems for Ophthalmic Drug Delivery (continued)

Emerging Delivery Systems for Ophthalmic Drug Delivery (continued)

Focus Areas of the Stakeholder Ecosystem

R&D Hubs Focusing on Ophthalmic Research

R&D Hubs Focusing on Ophthalmic Research (continued)

R&D Hubs Focusing on Ophthalmic Research (continued)

Recent Private Funding for the Development of Ophthalmic Therapies

Recent Private Funding for the Development of Ophthalmic Therapies (continued)

Co-development Collaborations

Co-development Collaborations (continued)

Recent Collaborations of Key Ophthalmology Industry Participants: Manufacturing

Recent Collaborations of Key Ophthalmology Industry Participants: Licensing

Growth Opportunity 1: Develop Targeted and Simple Delivery Systems

Growth Opportunity 1: Develop Targeted and Simple Delivery Systems (continued)

Growth Opportunity 2: Improve Disease Modeling and Early Diagnosis

Growth Opportunity 2: Improve Disease Modeling and Early Diagnosis (continued)

Growth Opportunity 3: Look Beyond Rare Ophthalmic Diseases

Growth Opportunity 3: Look Beyond Rare Ophthalmic Diseases (continued)

Clinical Pipeline of Key Players: Gene Therapy

Clinical Pipeline of Key Players: Gene Therapy (continued)

Clinical Pipeline of Key Players: Gene Therapy (continued)

Clinical Pipeline of Key Players: Gene Therapy (continued)

Clinical Pipeline of Key Players: Gene Therapy (continued)

Clinical Pipeline of Key Players: Gene Therapy (continued)

Clinical Pipeline of Key Players: Gene Therapy (continued)

Technology Readiness Levels (TRL): Explanation

Benefits and Impacts of Growth Opportunities

Next Steps

Take the Next Step

Legal Disclaimer